Key Takeaways
- • Renovus Capital has struck a deal to acquire Aspire, a Chicagoland home health provider headquartered in Morton Grove, Illinois.
- • Aspire was founded in 2013 and delivers skilled nursing and therapy to patients recovering at home from orthopedic procedures, surgeries and complex conditions.
- • The primary source available for this story is limited; deal value and terms were not disclosed in the material reviewed.
Summary
Renovus Capital has struck a deal for Aspire, a home health provider based in Morton Grove, Illinois, in the Chicago metropolitan area. The transaction was reported under the headline announcing Renovus's agreement for the company.
Founded in 2013, Aspire provides skilled nursing and therapy services to patients recovering at home. Its care focuses on individuals recovering from orthopedic procedures and surgeries, as well as patients managing complex medical conditions. The model positions the company within the growing home-based post-acute care segment, which serves as an alternative to facility-based rehabilitation.
The available source material does not include the purchase price, the size of the stake acquired, or the seller. Readers seeking those details should consult the full original reporting. Renovus Capital's broader investment focus and the specific rationale for the Aspire transaction were not detailed in the material reviewed.
Founded in 2013, Aspire provides skilled nursing and therapy services to patients recovering at home. Its care focuses on individuals recovering from orthopedic procedures and surgeries, as well as patients managing complex medical conditions. The model positions the company within the growing home-based post-acute care segment, which serves as an alternative to facility-based rehabilitation.
The available source material does not include the purchase price, the size of the stake acquired, or the seller. Readers seeking those details should consult the full original reporting. Renovus Capital's broader investment focus and the specific rationale for the Aspire transaction were not detailed in the material reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.